Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Quotient Ltd (QTNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
08/05/2021 8-K Quarterly results
Docs: "MosaiQ™ Solution o Transfusion Dx: Latest data confirms performance of MosaiQ Expanded IH; Expanded SDS microarray demonstrates excellent performance o Commercial Execution: Significant progress made with several customer evaluations scheduled; 25 separate distributor contacts established o New Market Segments: Successful proof of concept project further indicates full extent of MosaiQ by Quotient solution • Alba by Quotient: Revenues within guidance; Key future growth drivers identified and being pursued • Financial Position: Significantly strengthened balance sheet"
06/01/2021 8-K/A Quarterly results
02/01/2021 8-K Quarterly results
11/02/2020 8-K Quarterly results
Docs: "Quotient Limited Reports Second Quarter Fiscal 2021 Results and Business Update"
08/03/2020 8-K Quarterly results
06/09/2020 8-K Quarterly results
Docs: "Quotient Limited Provides Update on COVID-19 Antibody Test Progress, Other Key Developments and Fourth Quarter and Full Year Fiscal 2020 Results"
01/30/2020 8-K Quarterly results
Docs: "Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results"
11/04/2019 8-K Quarterly results
Docs: "Positive results from the initial Serological Disease Screening microarray US field trial • Positive Verification and Validation data for expanded Immunohematology microarray • An additional three Hypercare launch sites initiated in 2019 • Successful ISO 13485 : 2016 audit of MosaiQ microarray manufacturing facility • Second quarter product revenues ahead of plan growing 14% to $7.1 million JERSEY, Channel Islands, November 4, 2019 -- Quotient Limited , a commercial-stage diagnostics company, provided updates on several important developments in connection with the transformational MosaiQ multiplexing platform. These included successful preliminary results from the US field trial for the initial serological disease screening microarray paving the way for the fir..."
08/05/2019 8-K Quarterly results
Docs: "First European hypercare launch site initiated following CE mark approval • Initial Serological Disease Screening microarray submitted for CE marking • U.S. field trial activities for initial Serological Disease Screening commenced • 13 blood grouping reagents approved by the FDA for use with OEM automation • Record liquid reagent revenues recognized once again in the quarter JERSEY, Channel Islands, August 5, 2019 -- Quotient Limited , a commercial-stage diagnostics company, today provided an update on the commencement of its EU hypercare launch during July 2019; on the completion of its initial Serological Disease Screening microarray CE mark submission, which occurred in June 2019, and on the commencement of the initial SDS U.S. field trial last month. In add..."
05/28/2019 8-K Quarterly results
Docs: "CE mark received on the initial Immunohematology microarray in April 2019 • 2018 manufacturing site certification and MosaiQ TM device CE mark combine with the recent approval to permit commercialization • Successful European field trial drives the expectation of CE mark submission for the initial Serological Disease microarray in June 2019 • US field trials for initial Serological Disease and expanded IH microarrays planned to commence in the third calendar quarter of 2019 • Record quarterly reagent product revenues of $7.8 million, up 27.9% JERSEY, Channel Islands, May 28, 2019 -- Following the recent CE marking of its initial Immunohematology microarray, Quotient Limited , a commercial-stage diagnostics company, today provided an update on the status of its i..."
01/31/2019 8-K Quarterly results
11/05/2018 8-K Quarterly results
Docs: "Quotient Limited Reports Positive MosaiQ Audit Results and Instrument CE Mark with Second Quarter Fiscal 2019 Financial Results"
08/06/2018 8-K Quarterly results
Docs: "$48.8 million of proceeds from warrant exercises received through July 31 • $36 million of additional senior notes issued and funded in June • Initial SDS microarray verification and validation started • Record reagent revenues recorded during the quarter"
05/29/2018 8-K Quarterly results
Docs: "Agreement") is entered into as of May 24, 2018 , by and between Quotient Limited , or such affiliate of the Company as its Chairman of the Board of Directors of the Company may designate, and Franz Walt (the "Executive",
"MosaiQ European field trial which commenced on May 17, 2018 is ongoing • Franz Walt is appointed as Chief Executive Officer • Fourth quarter product revenues of $6.1 million, up 29.6%"
02/05/2018 8-K Quarterly results
Docs: "Manufacturing process change implemented with improved assay performance • Verification and Validation studies for blood grouping to resume • MosaiQ SDS Microarray preparing to enter into formal V&V studies • European Field Trials to commence following completion of V&V studies • Conventional reagent business continues strong revenue and profitability growth"
10/30/2017 8-K Quarterly results
08/07/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————————— FORM 8‑K ————————— CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934",
"Latest performance evaluation studies confirm substantial concordance with predicate technologies for blood grouping and initial diseases screening applications • European field trials expected to be completed in CY17 • Record reagent revenues recorded during the quarter, exceeding guidance • Six new reagent products licensed by the FDA for sale in the U.S."
02/06/2017 8-K Form 8-K - Current report
10/31/2016 8-K Form 8-K - Current report
08/08/2016 8-K Quarterly results
Docs: "FY17 Q1 EARNINGS RELEASE",
"Quotient Limited Reports Further Progress on the Commercial Scale-up of MosaiQ™ and First Quarter Fiscal 2017 Financial Results"
02/08/2016 8-K Form 8-K - Current report
11/02/2015 8-K Quarterly results
Docs: "UNITED STATESSECURITIES AND EXCHANGE COMMISSION",
"Quotient Limited Reports Second Quarter Fiscal 2016 Financial Results"
08/03/2015 8-K Quarterly results
Docs: "UNITED STATESSECURITIES AND EXCHANGE COMMISSION",
"Quotient Limited Reports First Quarter Fiscal 2016 Financial Results"
05/19/2015 8-K Quarterly results
Docs: "UNITED STATESSECURITIES AND EXCHANGE COMMISSION",
"Quotient Limited Reports Fourth Quarter and Full-Year Financial Results for the Year Ended March 31, 2015"
02/02/2015 8-K Quarterly results
Docs: "UNITED STATESSECURITIES AND EXCHANGE COMMISSION",
"Quotient Limited Reports Third Quarter Fiscal 2015 Financial Results"
11/03/2014 8-K Quarterly results
Docs: "UNITED STATESSECURITIES AND EXCHANGE COMMISSION",
"Quotient Limited Reports Second Quarter Fiscal 2015 Financial Results"
08/04/2014 8-K Quarterly results
Docs: "Quotient Reports First Quarter Fiscal 2015 Financial Results"
05/19/2014 8-K Quarterly results
Docs: "Quotient Limited Reports Fourth Quarter and Full-Year Financial Results for the Year Ended March 31, 2014 JERSEY, Channel Islands, May 19, 2014 — Quotient Limited , a commercial-stage diagnostics company, today reported financial results for its fourth quarter and fiscal year ended March 31, 2014. Financial highlights of the fourth quarter of fiscal 2014 include:"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy